Research programme: gastrointestinal sugar receptor modulators - Avaxia
Latest Information Update: 16 Jul 2016
At a glance
- Originator Avaxia Biologics
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 28 Jun 2010 Avaxia Biologics receives grant from the Massachusetts Life Sciences Center for antibody development in Obesity and Type-2 diabetes mellitus